These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 19458359

  • 1. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.
    Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D.
    Blood; 2009 Aug 20; 114(8):1618-27. PubMed ID: 19458359
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H, Huang F, Wang J, Wang P, Lv W, Hong L, Li S, Zhou J.
    Cell Cycle; 2015 Aug 20; 14(2):232-42. PubMed ID: 25607647
    [Abstract] [Full Text] [Related]

  • 10. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
    Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.
    Blood; 2008 Jan 01; 111(1):379-82. PubMed ID: 17878402
    [Abstract] [Full Text] [Related]

  • 11. Antileukemic activity of rapamycin in acute myeloid leukemia.
    Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B.
    Blood; 2005 Mar 15; 105(6):2527-34. PubMed ID: 15550488
    [Abstract] [Full Text] [Related]

  • 12. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.
    Liu L, Luo Y, Chen L, Shen T, Xu B, Chen W, Zhou H, Han X, Huang S.
    J Biol Chem; 2010 Dec 03; 285(49):38362-73. PubMed ID: 20937815
    [Abstract] [Full Text] [Related]

  • 13. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W, Ye Q, Liu S, She QB.
    Oncotarget; 2015 Jun 10; 6(16):13962-77. PubMed ID: 25961827
    [Abstract] [Full Text] [Related]

  • 14. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.
    Clin Cancer Res; 2010 Nov 15; 16(22):5424-35. PubMed ID: 20884625
    [Abstract] [Full Text] [Related]

  • 15. Relieving autophagy and 4EBP1 from rapamycin resistance.
    Nyfeler B, Bergman P, Triantafellow E, Wilson CJ, Zhu Y, Radetich B, Finan PM, Klionsky DJ, Murphy LO.
    Mol Cell Biol; 2011 Jul 15; 31(14):2867-76. PubMed ID: 21576371
    [Abstract] [Full Text] [Related]

  • 16. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.
    Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, Viollet B, Ifrah N, Dreyfus F, Hermine O, Moura IC, Lacombe C, Mayeux P, Bouscary D, Tamburini J.
    Blood; 2010 Nov 18; 116(20):4262-73. PubMed ID: 20668229
    [Abstract] [Full Text] [Related]

  • 17. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
    Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, Foster DA.
    Cell Cycle; 2011 Nov 15; 10(22):3948-56. PubMed ID: 22071574
    [Abstract] [Full Text] [Related]

  • 18. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
    Meng H, Jin Y, Liu H, You L, Yang C, Yang X, Qian W.
    J Hematol Oncol; 2013 Feb 18; 6():18. PubMed ID: 23415012
    [Abstract] [Full Text] [Related]

  • 19. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M.
    Oncotarget; 2015 Nov 10; 6(35):37930-47. PubMed ID: 26473447
    [Abstract] [Full Text] [Related]

  • 20. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q, Qin S, Zhang H, Liu B, Qin J, Wang X, Zhang R, Liu C, Dong X, Zhang S, Huang S, Chen L.
    J Cell Physiol; 2018 Jan 10; 233(1):516-529. PubMed ID: 28300280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.